Skip to content

Prospective Study for Transplant Optimization Using Functional Imaging (TROFI)

Prospective Study for Transplant Optimization Using Functional Imaging (TROFI)

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02488304
Enrollment
10
Registered
2015-07-02
Start date
2015-07-31
Completion date
2017-12-15
Last updated
2018-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiolitis Obliterans, Lung Transplant Rejection

Keywords

HRCT, High Resolution Computed Tomography scans, Functional Respiratory Imaging, FRI, Computed Tomography, CT, Bronchiolitis Obliterans Syndrome, BOS, Lung Transplant

Brief summary

The objective of this study is to detect BOS in an early stage by using the outcome parameters generated by Functional Respiratory Imaging (FRI). Robust and automated segmentation algorithms will be developed for these parameters, focusing on quantitative computed tomography (CT) image analyses to provide the physician a more sensitive diagnostics tool. The evolution of rejection over time will be monitored using non-rigid image registration methods.

Interventions

RADIATIONHRCT scans

A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 2, visit 3, visit 4, visit 5, visit 6, and visit 7. An upper airway (UA) scan will be taken on visit 2.

Sponsors

FLUIDDA nv
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female patient ≥ 18 years old * Written informed consent obtained * Patients who are planned to receive a lung transplant in the near future * Female patient of childbearing potential who confirm that a contraception method was used at least 14 days before screening visit and will continue to use a contraception method during the study * The patient must be able to perform the lung monitoring at home

Exclusion criteria

* Pregnant or lactating female * Known history of or active airways or anastomotic complications requiring intervention such as stenting or dilation

Design outcomes

Primary

MeasureTime frameDescription
Change in Airway Volume (iVaw) using FRI3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplantExploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7.
Change in Airway Resistance (iRaw) using FRI3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplantExploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7. Airway resistance is defined as the pressure drop over the airways divided by the airflow.
Change in Specific Airway Volume (siVaw) using FRI3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplantExploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7.
Change in Specific Airway Resistance (siRaw) using FRI3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplantExploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7.
Change in Lobe Volumes (iVlobes) using FRI3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplantExploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7.
Change in Air trapping using FRI3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplantExploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7. Air trapping is defined as the regions in the lung with a gray value on the CT-scan image smaller than -850 HU at functional residual capacity.
Change in Internal Lobar Airflow Distribution using FRI3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplantExploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7. Airflow distribution is defined in as the percentage of air going to every lobe when inhaling from FRC to TLC and is calculated for every lobe as: IALDlobe \[%\] = 100 (VTLC\_lobe - VFRC\_lobe) / (VTLC\_lungs - VFRC\_lungs).
Change in Low Attenuation or Emphysema Score using FRI3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplantExploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7.
Change in Blood Vessel Density or Fibrosis Score using FRI3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplantExploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7.
Change in Airway Wall Thickness using FRI3 months, 6 months, 9 months, 12 months, 18 months, and 24 months post-transplantExploratory imaging endpoints: HRCT scan will be taken at visit 2- visit 7.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026